FDA DEVICE FACTS
Confirm Rx Insertable Cardiac Monitor
Abbott
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
There ar e no changes to the Indications for Use as a result of this submission. The Indications for Use for the Confirm Rx™ ICM system are as follows: The Confirm Rx™ ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation. The Confirm Rx™ ICM has not been specifically tested for pediatric use. ABBOTT CONFIRM RX™ INSERTABLE CARDIAC MONITOR (DM3500) T RADITIONAL 510(k) K182981 PREMARKET NOTIFICATION SECTION 5 PRODUCT DESCRIPTION The device description of the Confirm Rx™ Insertable Cardiac Monitor (ICM) Model DM3500 is as follows: Confirm Rx™ ICM Model DM3500 Implantable Device: The ICM is intended as a minimally invasive, implantable diagnostic monitoring device, with subcutaneous electrodes, looping memory, and automatic as well as patient-activated EGM storage capability, which help physicians monitor, diagnose, and document patients who are susceptible to cardiac arrhythmias. It has a two-year longevity, MR conditional labeling, sensing and detection algorithms, and Bluetooth communication. Specific features include: o Patient-initiated triggering of EGM storage using the m yMerlin™ Patient App for mobile devices. This includes capability for the patient to identify symptoms, which are stored with the EGM for physician review. o Automated triggering of EGM storage when tachycardia, bradycardia, or pauses are detected; with physician -programmable values for pause duration, bradycardia rate, tachycardia rate, and number of tachycardia intervals. o Automated triggering of EGM storage when atrial fibrillation (AF) is detected, with physician programmable values for AF duration. o The ability to identify EGM anomalies as a consequence of noise or vigorous activity and inhibit EGM storage as applicable. o Remote care monitoring.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。